Free Newsletter
China evaluates the need for scientific failure
Chinese officials are mulling a new law that will officially sanction the value of scientific failure. A draft amendment to the Law on Science and Technology Process would clarify that scientists undertaking high-risk projects would not have to be concerned about the loss of future funding in light of a failed experiment. The top minister for science has been worried that scientists feel a considerable amount of pressure to report successes--particularly in the field of drug research. That's causing some researchers to steer away from the toughest projects--to say nothing about increasing the likelihood of fraudulent results. In drug research, of course, failure is a familiar feature in the field. And without regular failures, no one expects rapid progress.
- read the report on the proposed law from DrugResearcher.com
Related Articles:
China pushes drug development as R&D soars. Report
China now leads India in ongoing clinical trials. Report
Disgraced scientist back at work on cloned embryos. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession





SHARE
WITH: